Subscribe
fees-gavel-istock-542099686-tzahiv--1
tzahiV / iStockphoto.com
25 September 2017Americas

Gilead escapes enhanced damages in $2.5bn Idenix verdict

Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

More on this story

Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory